About Entrada Therapeutics
Innovating to transform the treatment of serious diseases through establishing a new class of genetic medicines.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Founded
- 2016
- Company type
- Public Company
Headquartered in Boston’s Seaport community, Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, we are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com
Company locations
One Design Center, Boston, MA 02210, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Health Care
- Biotechnology
- Genetics
- Medical
- Emergency Medicine
On LinkedIn
- Followers
- 35,719
- People linked to this company
- 205
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
301,599,999 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.